EMPEROR-Preserved confirms success of Empagliflozin in HFpEF Hina Zahid8 July 2021 9:45 AM ISTEmpagliflozin therapy with specific benefits in patients with heart failure and preserved ejection fraction (HFpEF) may finally be on its way as the...
SGLT2 inhibitors better than sulfonylureas for reducing deaths in type 2 diabetes: JAMA Medha Baranwal5 July 2021 11:45 AM ISTSt Louis, Missouri: The use of SGLT2 inhibitors may reduce the risk of all-cause mortality compared with sulfonylureas in patients with type 2...
SGLT2 inhibitors cause double weight loss than GLP-1 receptor agonists in diabetics: Study Hina Zahid3 July 2021 10:30 AM ISTAmong 72 patients, people using SGLT2 inhibitors experienced a median weight loss of more than 6 pounds, while those on GLP-1 receptor agonists lost a...
Finerenone improves kidney outcomes in patients of CKD with diabetes: Study Medha Baranwal2 July 2021 9:00 AM ISTDelhi: Finerenone exerts renoprotective benefits in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) irrespective of absence or...
SGLT2 inhibitors may reduce risk of kidney stone formation in diabetics: Study Medha Baranwal30 Jun 2021 10:00 AM ISTDenmark: Initiation of treatment with sodium-glucose cotransporter 2 inhibitors (SGLT2Is) may prevent incident and recurrent nephrolithiasis (kidney...
High-dose SGLT2 inhibitors tied to superior blood sugar control in type 2 diabetes: Study Medha Baranwal21 Jun 2021 11:44 AM ISTChina: The use of clinically approved high-dose SGLT2 inhibitors may help in improving blood sugar levels, body weight and blood pressure in patients...
How SGLT2 inhibitors slow CKD progression regardless of diabetes status, finds Study Hina Zahid14 Jun 2021 10:00 AM ISTThe researchers have experienced the first real breakthrough in the treatment of chronic kidney disease in a long time with SGLT2 inhibitors...
Dapagliflozin improves kidney and cardiac function in cases of FSGS kidney disease: Study Hina Zahid10 Jun 2021 9:00 AM ISTSGLT2 inhibitors offer a promising new therapeutic option in the field of nephrology and are likely to be used more extensively in future, both in...
SGLT2 inhibitors improve biomarkers indicative of CVD risk in diabetes patients: Study Medha Baranwal2 Jun 2021 9:30 AM ISTTurkey: Both dapagliflozin and empagliflozin significantly improve plasma atherogenic biomarkers (AIP and TyG indexes), an indicator of cardiovascular...
Exenatide-Dapagliflozin Combo Enhances Kidney Protection: DECREASE Trial Dr Kartikeya Kohli24 May 2021 7:30 PM ISTSodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs) are common hypoglycemic drugs. Previous...
SGLT2 Inhibitors Safe and Effective option for Diabetic Renal Transplant Patients Dr Kartikeya Kohli27 March 2021 11:30 AM ISTType 2 Diabetes, increasing in prevalence globally, is a major cause of CKD and kidney failure. In a recent study presented in ENDO 2021, The...
SGLT2 inhibitors and GLP1-receptor agonists reduce CHD risk in diabetes patients: Study Medha Baranwal22 March 2021 3:15 AM ISTItaly: Both SGLT2 inhibitors and GLP1-receptor agonists reduce the 10-year risk for cardiovascular disease in type 2 diabetes (T2D) patients without...
